FDA clears Tyber Medical’s Tibia Plating System
The Proximal Tibia Plating System is designed for both complete articular and partial articular fractures.
13 February 2024
13 February 2024
The Proximal Tibia Plating System is designed for both complete articular and partial articular fractures.
The investment into the software by Macmillan Cancer Support comes as part of a £3.5m ($4.3m) series of investments across the sector in a bid to improve cancer diagnoses.
The first-in-human trial of the Canary’s cardiac auscultation sensor device has been carried out in Paraguay.
The trial aims to determine the ability of the Clotild sensor to differentiate between various types of blood vessel blockages.
The approval allows all US patients implanted with the device, featuring the standard 45cm leads, to undergo 1.5T MRI scans.
The neurodegenerative disease is still mainly diagnosed after death, but advancements could help catch it earlier in living sports players.
The clearance comes on the heels of a multi-centre trial that found that the system was as effective in helping clinicians identify cancer with a 0.1% rate of discordance.
Factor Xa inhibitor concentration testing cannot be carried out by conventional coagulation tests.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.